<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639936</url>
  </required_header>
  <id_info>
    <org_study_id>TBnet study #54</org_study_id>
    <nct_id>NCT02639936</nct_id>
  </id_info>
  <brief_title>New Generation IGRA in Immunocompromised Individuals</brief_title>
  <acronym>TBnet#54</acronym>
  <official_title>Performance of a New Generation IGRA in Immunocompromised Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuberculosis Network European Trialsgroup</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tuberculosis Network European Trialsgroup</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of a new ELISA based interferon-gamma release assay (QuantiFERON TB plus In-tube
      test) in immunocompromized patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the performance of a new ELISA based QuantiFERON-TB plus
      In-tube test to identify M. tuberculosis specific immune Responses as evidence of latent
      infection with M. tuberculosis in immunosuppressed populations. Both qualitative and
      quantitative test results will be related to the level of immunodeficiency and to the
      presence of risk factors for prior exposure with M. tuberculosis. In addition, patients with
      active tuberculosis (both immunocompetent and immunocompromised individuals) will be included
      to evaluate a potential increase in sensitivity in these groups. Immunocompetent individuals
      with low risk of exposure will be analysed as a proxy to estimate specificity. Finally, this
      study will be extended to longitudinally assess the predictive value of a positive blood test
      for progression to active disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of negative test results will be quantified among controls and patients without risk factors for M. tuberculosis exposure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of positive test results will be quantified among controls and patients with active tuberculosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indeterminate results</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of indeterminate results will be quantified in immunocompetent and immunocompromised patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association with exposure</measure>
    <time_frame>2 years</time_frame>
    <description>Results from QFT-Plus assay will be associated with risk factors for M. tuberculosis exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression</measure>
    <time_frame>4 years</time_frame>
    <description>The number of individuals progressing to tuberculosis will be quantified depending on the test result at the time of screening and depending on preventive chemotherapy</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Monitoring, Immunologic</condition>
  <condition>Active Tuberculosis</condition>
  <condition>Tuberculosis in Solid Organ Transplant Recipients</condition>
  <condition>Tuberculosis in Marrow Transplant Recipients</condition>
  <condition>Tuberculosis in Rheumatoid Arthritis</condition>
  <condition>Tuberculosis in Chronic Renal Failure</condition>
  <condition>Tuberculosis in HIV-infected Individuals</condition>
  <arm_group>
    <arm_group_label>Immunocompetent controls</arm_group_label>
    <description>Control persons without immunodeficiency with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid organ transplant recipients</arm_group_label>
    <description>Patients after solid organ transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cell transplant recipients</arm_group_label>
    <description>Patients after stem cell transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis</arm_group_label>
    <description>Patients with rheumatoid arthritis with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with chronic renal failure</arm_group_label>
    <description>Patients with chronic renal failure with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individuals with HIV infection</arm_group_label>
    <description>Individuals with HIV infection with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stimulated plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Immunocompetent and immunocompromised patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals as specified for the study Population

          -  Written informed consent

        Exclusion Criteria:

          -  &lt;18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Sester, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Sester, PhD</last_name>
    <phone>0049-6841-16</phone>
    <phone_ext>23557</phone_ext>
    <email>martina.sester@uks.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Kopenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pernille Ravn, MD</last_name>
      <email>peravn@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Christine Nordholm, MD</last_name>
      <email>christinenordholm@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Åse Bengaard Andersen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research center Borstel</name>
      <address>
        <city>Borstel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Lange, MD PhD</last_name>
      <phone>49 4537 188</phone>
      <phone_ext>3320</phone_ext>
      <email>clange@fz-borstel.de</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Kalsdorf, MD</last_name>
      <email>bkalsdorf@fz-borstel.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Freiburg University</name>
      <address>
        <city>Freiburg</city>
        <zip>79100</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berit Lange, MD</last_name>
      <email>berit.lange@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>David Neyer</last_name>
      <email>dane86@gmx.net</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk Wagner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saarland University</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Sester, PhD</last_name>
      <phone>0049-6841-16</phone>
      <phone_ext>23557</phone_ext>
      <email>martina.sester@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Brescia and Brescia Spedali Civili General Hospital</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Matteelli, MD</last_name>
      <phone>+39 030 399</phone>
      <phone_ext>5802</phone_ext>
      <email>alberto.matteelli@unibs.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Raffaele Scientific institute</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela M Cirillo, MD PhD</last_name>
      <phone>+393333124</phone>
      <phone_ext>713</phone_ext>
      <email>cirillo.daniela@hsr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute for Infectious Diseases L. Spallanzani</name>
      <address>
        <city>Rome</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delia Goletti, MD PhD</last_name>
      <email>delia.goletti@inmi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology &amp; Allergology</name>
      <address>
        <city>Chisinau</city>
        <zip>2004</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dumitru Chesov, MD</last_name>
      <phone>+373 69961788</phone>
      <email>dumitru.chesov@usmf.md</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases; Oslo University</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Margarita Dyrhol-Riise, MD</last_name>
      <phone>4792857261</phone>
      <email>a.m.d.riise@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warszawski Uniwersytet Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Krawczyk, MD</last_name>
      <phone>0049 22 11 66 189</phone>
      <email>Marcin.Krawczyk@uniklinikum-saarland.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnóstico Pneumológico</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Duarte, MD PhD</last_name>
      <phone>35122375</phone>
      <phone_ext>5599</phone_ext>
      <email>raquelafduarte@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marius Nasta Institute of Pneumology</name>
      <address>
        <city>Bucharest</city>
        <state>Sector 5</state>
        <zip>5</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elmira Ibrahim, MD</last_name>
      <phone>40 21 335 69 10</phone>
      <phone_ext>1527</phone_ext>
      <email>ielmira2000@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut d'Investigació Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Domínguez, MD</last_name>
      <phone>+34 93 497 86 97</phone>
      <email>jadomb@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Neus Altet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malú de Souza Galvão, MD</last_name>
      <phone>34 93 301 24 24</phone>
      <email>maludesouzagalvao@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Arias Guillen, MD</last_name>
      <phone>0034 985108043</phone>
      <email>miguelariasguillen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lipman Marc, MD</last_name>
      <phone>02074726260</phone>
      <email>marclipman@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Brown James, MD</last_name>
      <phone>02074726260</phone>
      <email>james.brown13@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Moldova, Republic of</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.tb-net.org</url>
    <description>TBnet website</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

